Healthcare

Uwe Schoenbeck

Venture Partner / East Coast

Since 2024

Uwe Schoenbeck, Ph.D., is a Venture Partner at Canaan, an early-stage venture capital firm that invests in entrepreneurs with visionary ideas. Prior to joining Canaan, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer’s Worldwide Development & Medical (WRDM) division, where he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles. In addition to his business development activities, which included research collaborations, consortia, licensing, and acquisitions, he was also responsible for driving a cross-therapeutic portfolio via Pfizer’s dedicated academic partnering model, the Centers for Therapeutic Innovation (CTI). Before joining the Pfizer, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Dr. Schoenbeck received his degree from the University of Kiel in Germany and completed postdoctoral training in the Division of Cardiovascular Medicine at Brigham & Women’s Hospital at Harvard before joining as a faculty member. Dr. Schoenbeck has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, with particular contributions in molecular and cell biology, cardiovascular research, immunology, and metabolism.

Uwe in 5

Born in Hamburg, Germany; US 'Origin': Boston

Enjoy experiencing different cultures

Home projects & building houses

Helicopter pilot in Hawaii